StreetInsider.com News Articles

Form 4 OMEROS CORP For: May 22 Filed by: Cable Thomas J.

Wed, 27 May 2026 18:21:00 -0400

si-local-file:///var/storage/secattach/20260527/26559407.html

Form 4 OMEROS CORP For: May 22 Filed by: Cable Thomas J.

Wed, 27 May 2026 18:21:00 -0400

si-local-file:///var/storage/secattach/20260527/26559407.html

Form 144 OMEROS CORP Filed by: Cable Thomas J.

Fri, 22 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260522/26542361.html

Form 144 OMEROS CORP Filed by: Cable Thomas J.

Fri, 22 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260522/26542361.html

Omeros (OMER) Misses Q1 EPS by 12c

Wed, 13 May 2026 16:19:40 -0400

Omeros (NASDAQ: OMER) reported Q1 EPS of ($0.24), $0.12 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $9.89 million versus the consensus estimate of $40.15 million.

For earnings history and earnings-related data on Omeros (OMER) click here.

Omeros (OMER) Misses Q1 EPS by 12c

Wed, 13 May 2026 16:11:45 -0400

Omeros (NASDAQ: OMER) reported Q1 EPS of ($0.24), $0.12 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $9.89 million versus the consensus estimate of $40.15 million.

For earnings history and earnings-related data on Omeros (OMER) click here.

Form 10-Q OMEROS CORP For: Mar 31

Wed, 13 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260513/26485988.html

Form 10-Q OMEROS CORP For: Mar 31

Wed, 13 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260513/26485988.html

Form 8-K OMEROS CORP For: May 13

Wed, 13 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260513/26485965.html

Form 8-K OMEROS CORP For: May 13

Wed, 13 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260513/26485965.html

Omeros Corporation Reports First Quarter 2026 Financial Results

Wed, 13 May 2026 16:02:00 -0400

– Conference Call Today at 4:30 p.m. ET

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include:

First Quarter and Recent Highlights

In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million.

Net income for the first quarter of 2026 was $56.1 million, or $0.78 per share, compared to a net loss of $33.5 million, or

Omeros Corporation Reports First Quarter 2026 Financial Results

Wed, 13 May 2026 16:02:00 -0400

– Conference Call Today at 4:30 p.m. ET

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include:

First Quarter and Recent Highlights

In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million.

Net income for the first quarter of 2026 was $56.1 million, or $0.78 per share, compared to a net loss of $33.5 million, or

Omeros Corporation Reports First Quarter 2026 Financial Results

Wed, 13 May 2026 16:02:00 -0400

– Conference Call Today at 4:30 p.m. ET

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include:

First Quarter and Recent Highlights

In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million.

Net income for the first quarter of 2026 was $56.1 million, or $0.78 per share, compared to a net loss of $33.5 million, or

Omeros Corporation Reports First Quarter 2026 Financial Results

Wed, 13 May 2026 16:02:00 -0400

– Conference Call Today at 4:30 p.m. ET

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include:

First Quarter and Recent Highlights

In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million.

Net income for the first quarter of 2026 was $56.1 million, or $0.78 per share, compared to a net loss of $33.5 million, or

Omeros Corporation Reports First Quarter 2026 Financial Results

Wed, 13 May 2026 16:02:00 -0400

– Conference Call Today at 4:30 p.m. ET

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include:

First Quarter and Recent Highlights

In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million.

Net income for the first quarter of 2026 was $56.1 million, or $0.78 per share, compared to a net loss of $33.5 million, or

Omeros Corporation Reports First Quarter 2026 Financial Results

Wed, 13 May 2026 16:02:00 -0400

– Conference Call Today at 4:30 p.m. ET

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include:

First Quarter and Recent Highlights

In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million.

Net income for the first quarter of 2026 was $56.1 million, or $0.78 per share, compared to a net loss of $33.5 million, or

Omeros Corporation Reports First Quarter 2026 Financial Results

Wed, 13 May 2026 16:02:00 -0400

– Conference Call Today at 4:30 p.m. ET

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include:

First Quarter and Recent Highlights

In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million.

Net income for the first quarter of 2026 was $56.1 million, or $0.78 per share, compared to a net loss of $33.5 million, or

Omeros Corporation Reports First Quarter 2026 Financial Results

Wed, 13 May 2026 16:02:00 -0400

– Conference Call Today at 4:30 p.m. ET

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include:

First Quarter and Recent Highlights

In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million.

Net income for the first quarter of 2026 was $56.1 million, or $0.78 per share, compared to a net loss of $33.5 million, or

Omeros Corporation Reports First Quarter 2026 Financial Results

Wed, 13 May 2026 16:02:00 -0400

– Conference Call Today at 4:30 p.m. ET

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include:

First Quarter and Recent Highlights

In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million.

Net income for the first quarter of 2026 was $56.1 million, or $0.78 per share, compared to a net loss of $33.5 million, or

Omeros Corporation Reports First Quarter 2026 Financial Results

Wed, 13 May 2026 16:02:00 -0400

– Conference Call Today at 4:30 p.m. ET

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include:

First Quarter and Recent Highlights

In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million.

Net income for the first quarter of 2026 was $56.1 million, or $0.78 per share, compared to a net loss of $33.5 million, or

Omeros Corporation Reports First Quarter 2026 Financial Results

Wed, 13 May 2026 16:02:00 -0400

– Conference Call Today at 4:30 p.m. ET

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include:

First Quarter and Recent Highlights

In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million.

Net income for the first quarter of 2026 was $56.1 million, or $0.78 per share, compared to a net loss of $33.5 million, or

Omeros Corporation Reports First Quarter 2026 Financial Results

Wed, 13 May 2026 16:02:00 -0400

– Conference Call Today at 4:30 p.m. ET

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include:

First Quarter and Recent Highlights

In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million.

Net income for the first quarter of 2026 was $56.1 million, or $0.78 per share, compared to a net loss of $33.5 million, or

Omeros Corporation Reports First Quarter 2026 Financial Results

Wed, 13 May 2026 16:02:00 -0400

– Conference Call Today at 4:30 p.m. ET

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include:

First Quarter and Recent Highlights

In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million.

Net income for the first quarter of 2026 was $56.1 million, or $0.78 per share, compared to a net loss of $33.5 million, or

Omeros Corporation Reports First Quarter 2026 Financial Results

Wed, 13 May 2026 16:02:00 -0400

– Conference Call Today at 4:30 p.m. ET

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include:

First Quarter and Recent Highlights

In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million.

Net income for the first quarter of 2026 was $56.1 million, or $0.78 per share, compared to a net loss of $33.5 million, or

Omeros Corporation Reports First Quarter 2026 Financial Results

Wed, 13 May 2026 16:02:00 -0400

– Conference Call Today at 4:30 p.m. ET

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2026, which include:

First Quarter and Recent Highlights

In January 2026, we launched YARTEMLEA® in the U.S. market. During the quarter, gross product sales were $11.1 million and associated net sales, after deduction of wholesaler distribution fees and chargebacks, were $9.9 million.

Net income for the first quarter of 2026 was $56.1 million, or $0.78 per share, compared to a net loss of $33.5 million, or